Cargando…
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial
BACKGROUND: In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal an...
Autores principales: | Van Cutsem, Eric, Falcone, Alfredo, Garcia-Carbonero, Rocio, Komatsu, Yoshito, Pastorino, Alessandro, Peeters, Marc, Shimada, Yasuhiro, Yamazaki, Kentaro, Yoshino, Takayuki, Zaniboni, Alberto, Amellal, Nadia, Kanehisa, Akira, Winkler, Robert, Makris, Lukas, Mayer, Robert J, Ohtsu, Atsushi, Tabernero, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708320/ https://www.ncbi.nlm.nih.gov/pubmed/29215098 http://dx.doi.org/10.1136/esmoopen-2017-000261 |
Ejemplares similares
-
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017) -
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
por: Yoshino, T., et al.
Publicado: (2020) -
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
por: Tabernero, Josep, et al.
Publicado: (2020) -
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017) -
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
por: Van Cutsem, E., et al.
Publicado: (2022)